Recombinant adeno-associated viruses (rAAVs) can transduce several tissues, including the brain. However, in brain the duration of gene expression in different areas is variable, which has been ascribed to viral (CMV) promoter silencing in some regions over time. We have compared expression of enhanced green fluorescent protein (EGFP) in the nigrostriatal pathway of rats mediated by rAAVs containing the CMV or platelet-derived growth factor-␤ chain (PDGF-␤) promoter. In addition, we studied the effects of the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) on transgene expression in vivo. The rAAV vectors containing the neuron-specific PDGF-␤ chain promoter transduced significantly more dopaminergic neurons than
Introduction
Recombinant adeno-associated viruses (rAAVs) have been developed in the last few years as vectors for gene transfer and gene therapy. 1, 2 Infection with rAAV vectors allows the transduction of both dividing and quiescent cells without eliciting cellular immunity or toxicity, and leads to efficient long-term transgene expression in the absence of viral gene expression in several tissues, including the brain. [3] [4] [5] [6] [7] [8] Dendritic cells (DC) are potent antigen-presenting cells activating naive T cells to become cytotoxic T lymphocytes. Although rAAVs can enter DC, they fail to transduce DC productively due to a post-entry block of AAV-mediated gene transfer. 9 Inefficient transduction of DC by rAAVs may account for the low immunogenicity of this vector. However, it has been shown that induction of T cell immunity to antigens expressed by rAAVs depends on the route of administration, 10 and perhaps the antigen (K Jooss et al, unpublished). In brain, rAAV vectors are preferentially taken up and expressed by neurons, 11, 12 but the degree and the duration of AAV-mediated transgene expression varies depending on the injected area and the promoter used. 13, 14 Employing an AAV vector expressing ␤-titer-matched vectors carrying the CMV promoter. Moreover, the WPRE further increased EGFP expression, and a rAAV vector incorporating both the PDGF-␤ chain promoter and the WPRE resulted in efficient EGFP expression in dopaminergic neurons and their projections in the striatum for at least 41 weeks after virus injection. Our results emphasize the importance of a strong tissue-specific promoter in achieving optimal transgene expression, not only in longterm but also in short-term studies where viral titers may be limiting. Furthermore, they suggest that incorporation of the WPRE into rAAVs, and possibly other types of vectors, is useful to enhance transgene expression in vivo. Gene Therapy (2000) 7, 1304-1311.
galactosidase under the control of the CMV promoter, the most efficient short-term transduction (1 week after vector injection) was observed in the hippocampus and the piriform cortex, followed by the inferior colliculus, the olfactory tubercle and the caudate. 13 However, 3 months after virus delivery, expression was substantially reduced in the hippocampus and also in the caudate, while similar levels remained in the olfactory tubercle and the inferior colliculus. 13 Transduction for up to 3 months in the hippocampus was achieved with a vector incorporating the neuron-specific enolase (NSE) promoter.
14 Using the same virus dose, the latter study also showed that the NSE promoter-containing rAAV was six-fold more efficient in transducing neurons than a comparable CMV promoter-based vector. A bicistronic, NSE promoterdriven vector was also successfully used to transduce the rat nigrostriatal and septohippocampal pathways for up to 3 months. 15 Woodchuck hepatitis virus contains a post-transcriptional regulatory element (WPRE) that is required for the cytoplasmic accumulation of viral RNAs. 16 This element was recently shown to enhance expression of transgenes in transfected and infected cultured cells when incorporated into the 3Ј untranslated region. 17, 18 However, the effect of the WPRE on viral vector-mediated gene expression in vivo has not been assessed. In this study, we quantitatively compared expression of green fluorescent protein (EGFP) in the nigrostriatal pathway of rats 4 weeks after nigral injection with rAAV vectors carrying either the CMV promoter or the neuron-specific human platelet-derived growth factor-␤ (PDGF-␤) chain promoter. 19 In addition, we have studied the effects of the WPRE on EGFP expression levels in substantia nigra and striatum.
Results
Four different rAAV vectors were constructed ( Figure 1 ) and rAAVs produced by an adenovirus-free cotransfection method in 293T cells. The rAAV preparations were titrated in genomes/ml by quantitative real-time PCR and slot blot hybridization, and functionally titrated by FACS analysis or replication center assay (see Materials and methods). The titers are summarized in Table 1 . In order to evaluate the influence of promoter type and WPRE on the expression level of EGFP in vivo, the four different rAAV preparations were diluted to 2 × 10 10 genomes/ml. For each type of rAAV vector three rats were injected in a stereotactic frame dorsally to the substantia nigra of one hemisphere 5 with a total of 6 × 10 7 rAAV genomes (Table 1) . EGFP expression in sections of the substantia nigra was analyzed 4 weeks after rAAV injection by direct fluorescence microscopy. In addition, dopaminergic neurons were stained by immune histochemistry with a monoclonal antibody against rat tyrosine hydroxylase (TH). For each animal, EGFP-positive and TH-positive cells were counted in three sections containing the needle tract (one central and two adjacent sections). In addition, EGFP expression was analyzed in dopaminergic axons and the terminals in the striatum, Table 2 ). In a pairwise comparison, the percentages of transduced dopaminergic neurons were statistically different between PDGF-␤ vectors and CMV vectors (P Ͻ 0.001 or P Ͻ 0.01) (Figure 3a ). There was also a difference between the two PDGF-␤ vectors (P Ͻ 0.01) but not between the two CMV vectors (P Ͼ 0.1) (Figure 3a ). In conjunction with the PDGF-␤ promoter, the WPRE increased transduction in the substantia nigra about twofold (P Ͻ 0.01) (Figure 3a) . The total number of EGFP + neurons was also higher with the AAV-PDGF-EGFP-WPRE vector than with the two CMV viruses (P Ͻ 0.1) (Figure 3b ). However, there was no statistically significant difference in the overall numbers of EGFP + neurons between the other vector types (Figure 3b ). To assess the rostro-caudal extension of transduction in the substantia nigra, we determined the number of sections with at least 10 TH/EGFP double-positive neurons (n = 3 rats per group). By these criteria, 'positive' sections in AAV-CMV-EGFP-injected rats were found over a distance of 0.43 ± 0.14 mm and in AAV-CMV-EGFP-WPRE-injected animals within 0.46 ± 0.20 mm. The transduced areas for AAV-PDGF-EGFP and AAV-PDGF-EGFP-WPRE were Rats were injected in a streotactic frame dorsally to the substantia nigra (for coordinates, see Materials and methods). Images from brain sections (cut 4 weeks after infection) were taken with a Zeiss fluorescence microscope equipped with a Hamamatsu CCD camera and transferred to a Macintosh computer. TH + and EGFP + neurons were counted by an investigator blinded to the experiment using the NIH Object-Image software. Numbers represent mean ± s.d. from three 40 m sections surrounding the needle tract (n = 3 rats per vector type). A statistical analysis of the data is presented in Figure 3 . larger than 0.80 ± 0.10 and 1.10 ± 0.20 mm, respectively, since even the outermost sections that were available for analysis contained more than 10 double-positive neurons. In a pairwise comparison of the different rAAVs, the areas containing at least ten transduced dopaminergic neurons were significantly different for all vector pairs, except for the two CMV vectors (PDGF-WPRE versus PDGF: P Ͻ 0.1; PDGF-WPRE versus CMV-WPRE: P Ͻ 0.05; PDGF-WPRE versus CMV: P Ͻ 0.01; PDGF versus CMV-WPRE: P Ͻ 0.1; PDGF versus CMV: P Ͻ 0.05; CMV-WPRE versus CMV: P Ͼ 0.1).
rAAV vectors were injected dorsally to the substantia nigra of one hemisphere (for stereotactic coordinates, see Materials and methods). Four weeks later 40 m sections of the substantia nigra were analyzed for EGFP fluorescence (a, d, g, j) and stained for TH expression with a monoclonal antibody against rat tyrosine hydroxylase (b, e, h, k). c, f, i and l are overlays of EGFP and TH expression pictures of the same sections. Injected rAAVs were AAV-PDGF-EGFP-WPRE (a-c), AAV-PDGF-EGFP (d-f), AAV-CMV-EGFP-WPRE (g-i) and AAV-CMV-EGFP (j-l). Original magnification × 32 (scale bar: 0.4 mm).
Nigral injection of AAV-PDGF-EGFP-WPRE also resulted in strong EGFP expression in dopaminergic fibers in the caudate (Figure 4a -c) and in dopaminergic axon terminals throughout the striatum on the injected hemisphere (Figure 4d ), but not in the contralateral uninjected hemisphere (Figure 4e) , with the exception of some positive fibers that are known to cross over into the contralateral striatum. 20 In contrast, only occasional EGFPpositive fibers were detected by direct fluorescence microscopy in the ipsilateral striatum of the rats injected with the other types of vectors (data not shown). In order to determine whether transgene expression mediated by AAV-PDGF-EGFP-WPRE was stable, we analyzed nigral and striatal EGFP expression 22 weeks and 41 weeks after virus injection ( Figure 5 ). Quantification and statistical analysis of the number of EGFP + neurons and the percentage of transduced TH + neurons revealed that for both parameters transduction at 22 weeks and 41 weeks was similar to the transduction found at 4 weeks (Table 3 ). In the 41-weeks rat, EGFP expression was mostly confined to the lateral and caudal parts of the substantia nigra. Table 2 Inspection of the location of the needle tract showed that this correlated with a more lateral and caudal nigral injection of this animal. Since the projections of the substantia nigra to the striatum are topologically oriented, striatal expression of EGFP in this rat is also mostly lateral (Figure 5j and l) .
Discussion
Recombinant AAVs are promising vectors for gene transfer in the nervous system, where they allow expression Gene Therapy of transgenes in postmitotic neurons. 21 These vectors have been used to explore the neuroprotective potential of certain proteins in a number of animal models. Intranigral injection of rAAV-GDNF, for instance, induces significant protection of tyrosine hydroxylase (TH)-positive neurons in a rat model of Parkinson's disease. 5 Moreover, bilateral coinjection of rAAV-TH and rAAV-GTP cyclohydrolase into the striatum of dopamine-deficient mice restores feeding behavior for several months. 22 Most studies have used rAAV containing the human cytomegalovirus immediate-early gene (CMV) promoter. While the CMV promoter remains active for more than a year in skeletal muscle, 3 reductions over time in transgene expression levels in different areas of the brain have been described using the same promoter. [12] [13] [14] 23 In hippocampus, CMV promoter-driven GFP expression was reduced by 96% between 3 weeks and 3 months after infection, while expression remained stable over the same period with a neuron-specific enolase promoter.
14 CMV promoter silencing has also been demonstrated in some cultured cells and in the liver of transgenic mice, and may be due to hypermethylation 24 and/or a lack of endogenous activating transcription factors. 25 Most human neurodegenerative diseases progress over long periods of time. Therefore, in order to interfere with neuronal loss, therapeutic proteins will need to be expressed stably for months or even years, and in as many cells as possible, in areas of neurodegeneration. This probably requires gene expression under the control of a neuron-specific promoter. Platelet-derived growth factor-␤ is heavily expressed in neurons of the central nervous system, including the substantia nigra. 19 Furthermore, the PDGF-␤ chain promoter has been used to generate a mouse model of Alzheimer's disease by neuronal overexpression of a mutated Alzheimer precursor protein. 26 In Parkinson's disease, a progressive loss of dopaminergic neurons in the substantia nigra ultimately results in a dopamine deficiency and associated motor impairments. To develop an optimal vector for gene transfer to dopaminergic neurons, we compared EGFP transduction efficiencies of rAAV vectors carrying the CMV promoter or the PDGF-␤ chain promoter in the rat substantia nigra. 
Figure 5 Transduction at 22 weeks and 41 weeks after injection of AAV-PDGF-EGFP-WPRE. EGFP fluorescence (a, d, g, j) and TH immunoreactivity (b, e, h, k) in sections of the substantia nigra (a-c and g-i) and ipsilateral striatum (d-f and j-l) 22 weeks (a-f) and 41 weeks (g-l) after stereotactic injection of AAV-PDGF-EGFP-WPRE dorsally to the substantia nigra. (a-c) and (g-i) Original magnification × 64 (scale bar: 0.2 mm). (d-f) and (j-l) Original magnification × 16 (scale bar: 0.8 mm).
Our results clearly demonstrate the superiority of the PDGF-␤ chain promoter over the CMV promoter with respect to transduction efficiency in the substantia nigra, even at 4 weeks after virus injection. Based on other studies in which higher doses of rAAVs were used, it is unlikely that CMV promoter silencing is complete by 4 weeks. 12 Therefore, we believe that the increased transduction efficiency of rAAVs carrying the PDGF-␤ pro- moter results from an intrinsically higher activity of this promoter in neurons, rather than a CMV promoter silencing effect. This interpretation is supported by a recent study in which strong neuron-specific GFP expression was reported in the spinal cord after injection with a rAAV containing the PDGF-␤ promoter. 27 Under conditions of limiting viral titers as in this study, single neurons may be infected by only a few virions. Transgene expression under the control of a strong neuronal promoter may still be high enough for detection, whereas this may no longer be the case with a suboptimal promoter.
Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element (WPRE) that is required for the cytoplasmic accumulation of viral RNAs. 16 Incorporation of the WPRE into the 3Ј untranslated part of reporter constructs has been shown to increase reporter gene expression in transfected and infected cultured cells. 17, 18 However, the effect of the WPRE on in vivo transgene expression from a viral vector has not been previously tested. In our experiments, the best transduction of the nigrostriatal pathway was achieved with the rAAV vector carrying both the PDGF-␤ chain promoter and the WPRE. The percentage of transduced dopaminergic neurons with this vector was 1.8-fold higher than with the PDGF-␤ vector lacking the WPRE (P Ͻ 0.01). Moreover, while nigral infection with AAV-PDGF-EGFP-WPRE resulted in strong expression of EGFP in dopaminergic axons and striatal terminals, only occasional and weakly EGFP-positive fibers could be detected in the striatum of rats infected with AAV-PDGF-EGFP or the two CMV promoter-containing vectors. However, we cannot exclude that a low level of EGFP expression was present in the striatum of animals injected with these latter rAAV vectors but was not detected in the absence of GFP antibodies. 27 With respect to the PDGF-␤ vectors it is interesting to note that, despite high levels of chloramphenicol acetyltransferase (CAT) protein in neuronal cell bodies of PDGF-␤ promoter-CAT transgenic mice, CAT was absent in axons or terminals originating from positive cell bodies in most areas of the brain, and this pattern of transgene expression was found to be remarkably similar to the localization of authentic PDGF-␤. 19 This result is also strikingly similar to the situation with AAV-PDGF-EGFP, which yields readily detectable EGFP expression in the substantia nigra, but not in axons emerging from the transduced neuronal bodies. The fact that the WPRE significantly increases striatal EGFP expression from the PDGF-␤ promoter, while increasing transduction in the substantia nigra by only 1.8-fold, suggests that the WPRE strongly increases EGFP expression in individual transduced neurons. In fact, previous studies in cultured cells showed that the WPRE exerts its stimulatory effect by increasing both the steady-state level of mRNA and the efficiency of translation, thus allowing higher levels of transgene expression to be achieved per transduction event. 18 Moreover, it was shown that the WPRE increases expression from both intron-less and spliced mRNAs. 17 Finally, we demonstrate that EGFP transduction mediated by AAV-PDGF-EGFP-WPRE remains stable for at least 41 weeks in both the substantia nigra and the striatal dopaminergic terminals. To our knowledge, this is the longest period of gene expression demonstrated in the nigrostriatal pathway by any viral vector. Our results emphasize the importance of a strong tissue-specific promoter in achieving optimal transgene expression, not only in the long-term but also in short-term studies under circumstances where viral titers may be limiting. Furthermore, they suggest that it may be useful to incorporate the WPRE into other (viral) gene transfer vectors to enhance transgene expression in vivo. The AAV-PDGF-WPRE vector backbone should be useful for developing treatments for Parkinson's disease that rely on cellautonomous effects of candidate therapeutic proteins as well as the secretion of neurotrophic factors.
Materials and methods

Plasmid constructions
The EcoRI/HindIII CMV-lacZ-polyA expression cassette from plasmid pCMV-␤ (Clontech, Basel, Switzerland) was inserted between the XbaI sites of psub201 28 to generate the plasmid psubCMV-␤. Subsequently, the NotI/NotI ␤-galactosidase fragment of psubCMV-␤ was excised and replaced by a multiple cloning site (NotI, AceII, NheI, PmlI, MluI, Acc65I, KpnI), generated by hybridization of the oligodeoxynucleotides 5ЈGGCCGCAGCCATGGGCT AGCACGTGACGCGTGGTACC3Ј and 5ЈGGCCGGTAC-CACGCGTCACGTGCTAGCCCATGGCTGC3Ј, to produce plasmid psubCMV. To generate psubCMV-WPRE, the 0.59 kb ClaI/ClaI WPRE fragment from p138WPRE 16 was inserted into the KpnI site of psubCMV. psubPDGF-WPRE was constructed by cloning a 1.48 kb XbaI/SalI fragment of the human PDGF-␤ chain promoter 19 between the EcoRI and XhoI sites of psubCMV-WPRE. psubCMV-EGFP was constructed by inserting the SmaI/HpaI EGFP fragment from pEGFP-N1 (Clontech) into the PmlI site of psubCMV. Plasmid psubCMV-EGFP-WPRE was obtained by inserting the same EGFP fragment into the PmlI site of psubCMV-WPRE. To construct psubPDGF-EGFP, the 1.48 kb XbaI/SalI fragment of the human PDGF-␤ chain promoter was cloned between the EcoRI and XhoI sites of psubCMV-EGFP. psubPDGF- Production and titration of rAAV Twenty 175 cm 2 tissue culture plates with 70-80% confluent 293T cells in DMEM-10% fetal calf serum (FCS) were cotransfected by the calcium phosphate method with rAAV vector plasmid, AAV packaging plasmid pAAV/Ad-rep(ACG) and adenovirus helper plasmid pBS-E2A-VA-E4 (1:1:1 molar ratio). Fourteen hours later, the transfection medium was replaced by fresh DMEM-10% FCS. Cells were collected 60 h after transfection in their medium and rAAVs were released from the cells and purified by two rounds of CsCl gradient centrifugation and dialysis, as described. 29 rAAV particle (genome) titers were determined by quantitative realtime PCR in the LightCycler (Roche Diagnostics, Rotkreuz, Switzerland) using the transgene-specific primers 5ЈGCGCTAGCCACCATGGTGAGCAAG3Ј and 5ЈCGGCT AGCCTTGTACAGCTCGTCCATG3Ј and SYBRGreen (Roche Molecular Biochemicals, Rotkreuz, Switzerland) in the reaction mixture. As a standard, an EGFP plasmid diluted to known concentrations (number of templates) was used. Titers of rAAV vectors were between 4.7 × 10 10 and 4.6 × 10 11 genomes/ml, and comparable with the titers obtained by slot blot hybridization. 29 
Animals and surgery
Animals were bred at the Institute of Toxicology of the ETH Zurich and housed under specific pathogen-free conditions on a 12 h light/dark cycle with free access to food and water. Male Wistar rats (9 weeks old; 285 ± 14 g) were anesthesized with an intraperitoneal injection of Nembutal (50 mg/kg body weight) (Abbott Laboratories, North Chicago, IL, USA), and received 0.1 ml atropine (0.5 mg/ml) (Sintetica, Mendrisio, Switzerland) subcutaneously to prevent respiratory problems. Intracranial injections of rAAV were done in a stereotactic frame (Kopf Instruments, Tujunga, CA, USA). rAAV was injected at two coordinates above the substantia nigra (AP −5.4 mm, ML +2.8 mm, DV −7.2 mm and AP −5.4 mm, ML +1.8 mm, DV −7.6 mm relative to bregma; 1.5 l per site) at a speed of 0.5 l/min using a sp200i syringe pump (World Precision Instruments, Boston, MA, USA) and a 10 l Hamilton syringe fitted with a 26-gauge steel cannula. After injection, the cannula was left in place for another 2 min and then slowly retracted. All treatments were in accordance with institutional and national guidelines.
EGFP expression analysis and TH immune histochemistry Deeply anesthesized rats were perfused intracardially with 4% paraformaldehyde in phosphate-buffered saline (4% PFA/PBS). Brains were removed, postfixed for 2 h at 4°C in 4% PFA/PBS and cryoprotected overnight in 30% sucrose/PBS at 4°C. Forty m coronal cryosections throughout the anterior-posterior extension of the substantia nigra as well as sections of the striatum were cut on a microtome (Microm, Walldorf, Germany). EGFP expression was visualized by direct fluorescence microscopy. To stain dopaminergic neurons and fibers, sections of the substantia nigra and the striatum were incubated with 1:1500 diluted monoclonal antibody TOHA1.1 against rat tyrosine hydroxylase (Becton Dickinson, Basel, Switzerland). Secondary antibodies were rhodamine-conjugated (1:400 dilution) or Cy3-conjugated (1:600 dilution) anti-mouse IgG antibodies (Milan Analytica AG, La Roche, Switzerland).
Imaging and cell quantifications
Images were captured by a Zeiss microscope (Carl Zeiss, Feldbach, Switzerland) connected to a Hamamatsu CCD camera. In order to cover the whole substantia nigra of the injected hemisphere, images of three slightly overlapping visual fields of the sections were taken with the 10 × lens, using FITC (for EGFP expression) or Cy3 (for TH expression) filter sets. The filter sets completely separated the emission spectra of FITC and Cy3. Images were transferred to a Macintosh computer and processed using the Adobe Photoshop 5.0 software. EGFP-and TH-positive neurons were counted manually on the screen using the NIH Object-Image software. FITC-and Cy3-filtered images of the same sections were superimposed to count EGFP/TH double-positive neurons.
Statistics
The number of EGFP + neurons, the percentage of transduced dopaminergic neurons and the areas of transduction in the substantia nigra were analyzed statistically with the Student's t test for independent samples.
